FDA Used Critically Flawed Risk-Benefit Analysis to Justify COVID Vaccines For Children

The US FDA used a ‘critically flawed’ risk-benefit analysis to ‘justify’ COVID vaccines for children. The hazards of COVID-19 vaccination exceed the advantages for millions of children.

On October 29, 2021, the US Food and Drug Administration (FDA) issued Pfizer’s COVID-19 vaccine Emergency Use Authorization (EUA) for children aged 5 to 11.

On Nov. 2, 2021, the Centers for Disease Control and Prevention (CDC) recommended Pfizer’s COVID-19 vaccination for 28 million American kids under the age of 5 to 11.

Pfizer petitioned the FDA this week to approve the administration of a two-dose vaccination in children aged 6 months to 4 years. When statistics on a third shot becomes accessible in the spring, it will be presented to authorities, paving the path for the government to approve a three-shot program for the youngest infants who could be immunized. This age group’s vaccination might be ready as early as February.

Upon vaccination with Pfizer’s COVID-19 vaccine, the FDA and CDC safety monitoring programs discovered an elevated risk of cardiac inflammation (myocarditis/pericarditis). This danger was shown to be greatest in 12- to 17-year-old males, especially after the...

Read More HERE